The National Association of Community Health Centers (NACHC) told drug manufacturer Gilead this morning its new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments are “unconscionable,” “appalling,” “wrongheaded,” and “the latest example of corporate greed from
…
UPDATE Friday, March 18, 2022, 1:30 p.m. EDT—The U.S. Health Resources and Services Administration (HRSA) told 340B Report shortly after this story was published, “To be eligible, [a] hospital’s termination must have been as a result of actions taken by
…
Gilead late yesterday imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies. It is the 15th manufacturer to place restrictions on its 340B contract pharmacy program.
The policy, which applies to hospital
…
The U.S. Senate last night passed a $1.5 trillion federal appropriations bill with language to help some hospitals forced out of the 340B program during the COVID-19 pandemic.
The House passed the bill Wednesday night. President Biden is expected
…
Legislation addressing hospitals’ loss of eligibility for 340B drug discounts due to COVID-19-related changes in payer mix could reach President Biden before Friday at midnight. The language would not be as beneficial to such hospitals as standalone bipartisan bills in
…*Sign up for news summaries and alerts from 340B Report